Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned
Abstract Antibody–drug conjugates (ADCs) have emerged as a novel therapeutic strategy that has successfully reached patient treatment in different clinical scenarios. ADCs are formed by an antibody against a specific tumor-associated antigen (TAA), a cytotoxic payload, and a chemical linker that bin...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-12-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | https://doi.org/10.1186/s13045-023-01519-0 |